12:00 AM
Oct 13, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zanolimumab: Development discontinued

Genmab said it will discontinue development of zanolimumab, though patients already enrolled in an ongoing Phase III trial for CTCL and a Phase II trial for non-cutaneous T cell lymphoma (NCTCL)...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >